Migal had been using BIOVIA applications in addition to an array of computational tools for four years of multidisciplinary research on avian coronavirus vaccine development projects. When COVID-19 became a pandemic, this academic research and development center – which focuses on plant science, agriculture, environmental science, computer science, nutrition and biotechnology – began using these applications and computational tools to apply its research to the study of COVID-19 mutations, with a view to deliver a novel coronavirus vaccine for humans for in vivo pre-clinical testing within 90 days.
In the context of COVID-19, Dassault Systèmes’ 3DEXPERIENCE platform and digital applications can help the healthcare ecosystem address research and clinical development to manufacturing and patient care.
By using BIOVIA for its COVID-19 R&D, Migal Galilee Research Institute can guide its laboratory and experiment management processes with a digital approach that speeds research results. Its scientists can quickly process and analyze the research data gathered during the past four years and model viral protein behavior and the evolution of its predicted neutralization epitopes. This enables them to rationalize the test results from different aspects of their past research and decide which research strategies to take going forward.
BIOVIA Pipeline Pilot streamlines the research innovation cycle by supporting the rapid development and deployment of data science workflows that accelerate the generation of actionable scientific insights. BIOVIA Discovery Studio delivers a comprehensive set of modeling and simulation methods to explore the nuances of protein chemistry and drive the discovery and development of small and large molecule therapeutics from target ID to lead optimization.
